Presentation TCT 2017 Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? No, Based on HORIZONS-AMI, PLATO, PEGASUS, and Other Studies! Presenter: John A. Bittl, Freek W.A. Verheugt, Gennaro Giustino October 30, 2017
Presentation TCT 2017 Strengths and Limitations of Composite Endpoints (eg, EXCEL, PLATO, and Others) Presenter: Roxana Mehran, Robert W. Yeh, Stuart J. Pocock October 30, 2017
News Daily News Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI Yael L. Maxwell October 03, 2017
News Daily News New Performance and Quality Metrics for STEMI and NSTEMI Care Michael O'Riordan September 21, 2017
News Conference News ESC 2017 CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS Todd Neale August 30, 2017
News Daily News CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition Michael O'Riordan August 04, 2017
News Conference News EuroPCR 2017 Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate Caitlin E. Cox May 22, 2017
News Conference News EuroPCR 2017 TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS Yael L. Maxwell May 16, 2017
News Daily News The Long and Short of It: DAPT Duration Choice After Stenting Gets Help From New Score Todd Neale March 10, 2017
News Daily News Ticagrelor More Effective Than Clopidogrel in ACS-With No Extra Bleeding Kim Dalton August 30, 2009